Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42


A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.

Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F, Weinstock-Guttman B.

Ther Adv Neurol Disord. 2015 Mar;8(2):59-70. doi: 10.1177/1756285615572953.


Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.

Craddock J, Markovic-Plese S.

Expert Rev Clin Pharmacol. 2015 May;8(3):283-96. doi: 10.1586/17512433.2015.1036030.


IL-11 Induces Th17 Cell Responses in Patients with Early Relapsing-Remitting Multiple Sclerosis.

Zhang X, Tao Y, Chopra M, Dujmovic-Basuroski I, Jin J, Tang Y, Drulovic J, Markovic-Plese S.

J Immunol. 2015 Jun 1;194(11):5139-49. doi: 10.4049/jimmunol.1401680. Epub 2015 Apr 20.


Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.

Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F.

J Neuroimmunol. 2015 Apr 15;281:44-50. doi: 10.1016/j.jneuroim.2015.03.002. Epub 2015 Mar 5.


The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.

Blauth K, Zhang X, Chopra M, Rogan S, Markovic-Plese S.

Clin Immunol. 2015 Apr;157(2):121-32. doi: 10.1016/j.clim.2015.01.001. Epub 2015 Jan 14.


Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder.

Delman D, Peng X, Zedek DC, Jewells V, Chahin N, Markovic-Plese S.

J Neuroimmunol. 2015 Jan 15;278:108-11. doi: 10.1016/j.jneuroim.2014.07.016. Epub 2014 Jul 30.


The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.

Tao Y, Zhang X, Chopra M, Kim MJ, Buch KR, Kong D, Jin J, Tang Y, Zhu H, Jewells V, Markovic-Plese S.

J Immunol. 2014 Jun 15;192(12):5610-7. doi: 10.4049/jimmunol.1302580. Epub 2014 May 21.


Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.

Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B.

PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014.


Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Freedman MS, Kaplan JM, Markovic-Plese S.

J Clin Cell Immunol. 2013 Jul 8;4(4). pii: 1000152.


Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S.

J Immunol. 2013 Dec 15;191(12):5867-74. doi: 10.4049/jimmunol.1301926. Epub 2013 Nov 6.


Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.


Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.

Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S.

Eur J Immunol. 2013 Jan;43(1):281-9. doi: 10.1002/eji.201242566. Epub 2012 Dec 6.


Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate.

Brück W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, Metz I.

Ann Neurol. 2012 Sep;72(3):385-94. doi: 10.1002/ana.23621.


Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis.

Li Y, Jewells V, Kim M, Chen Y, Moon A, Armao D, Troiani L, Markovic-Plese S, Lin W, Shen D.

Hum Brain Mapp. 2013 Dec;34(12):3376-91. doi: 10.1002/hbm.22158. Epub 2012 Sep 15.


Pathogenic features of CD4+CD28- T cells in immune disorders.

Broux B, Markovic-Plese S, Stinissen P, Hellings N.

Trends Mol Med. 2012 Aug;18(8):446-53. doi: 10.1016/j.molmed.2012.06.003. Epub 2012 Jul 10. Review.


Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis.

Ramgolam VS, Markovic-Plese S.

J Signal Transduct. 2011;2011:635721. doi: 10.1155/2011/635721. Epub 2011 Nov 1.


CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients.

Broux B, Pannemans K, Zhang X, Markovic-Plese S, Broekmans T, Eijnde BO, Van Wijmeersch B, Somers V, Geusens P, van der Pol S, van Horssen J, Stinissen P, Hellings N.

J Autoimmun. 2012 Feb;38(1):10-9. doi: 10.1016/j.jaut.2011.11.006. Epub 2011 Nov 26.


Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.

Zhang X, Tao Y, Troiani L, Markovic-Plese S.

J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.


Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Meeker RB, Poulton W, Markovic-Plese S, Hall C, Robertson K.

J Neurovirol. 2011 Jun;17(3):258-73. doi: 10.1007/s13365-011-0034-5. Epub 2011 May 10.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk